Tun AM, Wang Y, Maliske S, et al. - Researchers investigated if time to relapse and response to salvage therapy could impact post-autologous stem cell transplant (ASCT) results in patients with relapsed or refractory (RR) diffuse large B-cell lymphoma (DLBCL). This study included 437 DLBCL patients that relapsed following R-CHOP or R-CHOP-like frontline therapy who received salvage therapy and ASCT. Findings revealed that needing more than 1 line of salvage therapy and failure to achieve complete response, in RR DLBCL patients post-frontline immunochemotherapy, were observed as strong independent risk factors for poor progression-free survival and overall survival post-ASCT. In this patient population, study of novel therapies such as CAR-T cell therapy is recommended.